相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Different Pharmaceutical Products Need Similar Terminology
Daan J. A. Crommelin et al.
AAPS JOURNAL (2014)
How to Regulate Nonbiological Complex Drugs (NBCD) and Their Follow-on Versions: Points to Consider
Huub Schellekens et al.
AAPS JOURNAL (2014)
Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines
Falk Ehmann et al.
NANOMEDICINE (2013)
The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?
Stefan Muhlebach et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2013)
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy
Daniel Zucker et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Doxil® - The first FDA-approved nano-drug: Lessons learned
Yechezkel (Chezy) Barenholz
JOURNAL OF CONTROLLED RELEASE (2012)
Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome
Janos Szebeni et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2012)
Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies
Gerrit Borchard et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2012)
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
Janos Szebeni et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
The therapeutic equivalence of complex drugs
Huub Schellekens et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2011)
In vitro and in vivo characterizations of PEGylated liposomal doxorubicin
Wenlei Jiang et al.
BIOANALYSIS (2011)
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
Steven K. Libutti et al.
CLINICAL CANCER RESEARCH (2010)
Pegylated liposomal doxorubicin in the management of ovarian cancer
Gabriella Ferrandina et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2010)
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
H. Maeda et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2009)
Protein nanoparticles as drug carriers in clinical medicine
Michael J. Hawkins et al.
ADVANCED DRUG DELIVERY REVIEWS (2008)
Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin
Rebecca Solomon et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
The carbon nanotube patent landscape in nanomedicine: an Expert opinion
Drew L. Harris et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Dai Fukumura et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor
Jeffrey M. Farma et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery
GF Paciotti et al.
DRUG DELIVERY (2004)
Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors
B van Etten et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Liposome application: problems and prospects
Y Barenholz
CURRENT OPINION IN COLLOID & INTERFACE SCIENCE (2001)
分享论文
